Clinical Trial Update: Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sorafenib for relapsed chronic lymphocytic leukemia was terminated; results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2014-04-10